NPCA Annual Report 2022

The National Prostate Cancer Audit (NPCA) determines whether the care received by men diagnosed with prostate cancer in England and Wales is consistent with current recommended practice and provides information to support healthcare providers, commissioners and regulators in helping improve care for patients. The NPCA reports on process and outcome measures from all aspects of the care pathway for men with prostate cancer.

In the 2022 Annual Report, we present the results for men diagnosed with, or treated for, prostate cancer between 1st April 2020 and 31st March 2021 in England and Wales including:

1. The participation of NHS providers and the completeness and quality of the data submitted to the National Cancer Registration and Analysis Service (NCRAS), NHS Digital and the Wales Cancer Network, Public Health Wales.

2. Patient demographic information and key aspects of the diagnostic and staging process they underwent and the treatments they received.

3. Treatment outcomes (up to two years post-treatment) for men in England and Wales undergoing radical prostatectomy (RP) or radical external beam radiotherapy (EBRT) in 2018-2019.

4. The variation in treatment for men with low-risk, localised disease and high-risk/locally advanced disease in Wales only.

In addition, we also present:

5. The ongoing impact of COVID-19 on the diagnosis of prostate cancer, receipt of radical treatment and systemic therapy in England in 2021.

6. The impact of COVID-19 on the diagnosis of prostate cancer and receipt of radical treatment in Wales in 2020 and early 2021 (Q1).

国家前列腺癌审计（NPCA）旨在评估英格兰和威尔士地区被诊断为前列腺癌的男性患者所接受的护理是否与现行推荐实践保持一致，并为医疗机构、支付方和监管机构提供信息，以支持改善患者护理。NPCA对前列腺癌患者护理路径的各个方面进行过程和结果指标的报告。

在2022年度报告中，我们展示了2020年4月1日至2021年3月31日期间在英格兰和威尔士被诊断为或接受治疗的前列腺癌患者的相关结果，包括以下内容：

1. 国家卫生服务提供者的参与度，以及提交至国家癌症登记与分析服务（NCRAS）、NHS数字和威尔士癌症网络、公共卫生威尔士的数据的完整性和质量。

2. 患者的人口统计学信息，以及他们所经历的诊断和分期过程的关键方面，以及他们所接受的治疗。

3. 2018-2019年度在英格兰和威尔士接受根治性前列腺切除术（RP）或根治性体外放疗（EBRT）的男性的治疗结果（治疗后的两年内）。

4. 仅在威尔士，针对低风险局部疾病和高风险/局部晚期疾病男性的治疗方案差异。

此外，我们还展示了以下内容：

5. 2021年COVID-19对英格兰前列腺癌诊断、根治性治疗和系统性治疗持续产生的影响。

6. 2020年和2021年第一季度（Q1）COVID-19对威尔士前列腺癌诊断和根治性治疗产生的影响。